An ALKBH3 Inhibitor HUHS199 Suppresses Proliferation of Glioblastoma Cells by Targeting 1‐Methyladenosine on GADD45A mRNA
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70385 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2026. Written by Manami Yamada and 10 co-authors. Institution: Laboratory of Stem Cell Regeneration and Adaptation, Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Osaka, Japan. Major MEDLINE topics: Glioblastoma, AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase, Adenosine, Cell Cycle Proteins. 66 references. The full text is freely available (open access, CC BY 4.0). Funded by: MEXT, BINDS, JST SPRING.
Abstract (original language)
Glioblastoma (GBM) is a highly aggressive, poor‐prognosis brain tumor classified as WHO grade IV, for which effective treatments remain limited. Although AlkB homolog 3 (ALKBH3), a demethylase for 1‐methyladenosine (m1A) and 3‐methylcytidine (m3C) in DNA and RNA, has been implicated in cancer cell proliferation, its functional role in GBM remains unclear. We aimed to characterize the role of ALKBH3 in GBM and develop and evaluate a patented ALKBH3 inhibitor, HUHS199, to identify its molecular targets and therapeutic potential. We found that ALKBH3 was highly expressed in clinical GBM specimens; its knockdown inhibited GBM cell proliferation. HUHS199 inhibited GBM cell proliferation in a dose‐dependent manner, induced G1 phase cell cycle arrest, and increased m1A levels in RNA. Furthermore, RNA immunoprecipitation–microarray analysis using an anti‐m1A antibody identified growth arrest and DNA‐damage‐inducible protein GADD45 alpha (GADD45A) mRNA as a target of ALKBH3‐mediated demethylation. These findings suggest that ALKBH3 promotes GBM cell proliferation via m1A demethylation of GADD45A mRNA. Collectively, this study highlights the therapeutic potential of ALKBH3 inhibition and presents HUHS199 as a first‐in‐class candidate for GBM treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Laboratory of Stem Cell Regeneration and Adaptation, Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Osaka, Japan.
- Library Screening Center, Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Osaka, Japan.
- Drug Discovery Center, Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Osaka, Japan.
- Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
- Department of Neurosurgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
ORCID profiles: Hiroaki Hase, Toshiya Morie, Tatsuhiko Furukawa, Nayuta Higa, Ryosuke Hanaya
Funding
- MEXT
- BINDS
- JST SPRING
- Ministry of Education, Culture, Sports, Science and Technology
Cite
APA
Yamada, M., Hase, H., Kitamura, H., Morie, T., Aoi, S., Ueda, Y., Kitae, K., Furukawa, T., Higa, N., Hanaya, R., & Tsujikawa, K. (2026). An ALKBH3 Inhibitor HUHS199 Suppresses Proliferation of Glioblastoma Cells by Targeting 1‐Methyladenosine on GADD45A mRNA. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70385
Vancouver
Yamada M, Hase H, Kitamura H, Morie T, Aoi S, Ueda Y, et al. An ALKBH3 Inhibitor HUHS199 Suppresses Proliferation of Glioblastoma Cells by Targeting 1‐Methyladenosine on GADD45A mRNA. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70385
BibTeX
@article{Yamada2026,
author = {Yamada, Manami and Hase, Hiroaki and Kitamura, Honoka and Morie, Toshiya and Aoi, Shuntaro and Ueda, Yuko and Kitae, Kaori and Furukawa, Tatsuhiko and Higa, Nayuta and Hanaya, Ryosuke and Tsujikawa, Kazutake},
title = {An ALKBH3 Inhibitor HUHS199 Suppresses Proliferation of Glioblastoma Cells by Targeting 1‐Methyladenosine on GADD45A mRNA},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70385}
}
EUVIMED